


# WHEN PULMONARY FIBROSIS IS SUSPECTED, WHAT'S NEXT FOR ANN?



## MEDICAL HISTORY:

- 40-year-old Asian woman<sup>1-3</sup>
- Diagnosed with mixed connective tissue disease 15 years ago<sup>1,4</sup>
- Current smoker<sup>3</sup>
- History of tachycardia<sup>1</sup>
- Current treatments: beta blocker, NSAID, immunosuppressant<sup>5</sup>

## CLINICAL EVALUATION:

- Dyspnea<sup>1</sup>
- Dry inspiratory crackles at the lung bases<sup>1</sup>
- Reduced PFTs with restriction<sup>1</sup>

## RADIOLOGIC FINDINGS:

- Fibrotic ILD confirmed by features consistent with an NSIP pattern<sup>1</sup>:
  - Subpleural sparing
  - Bilateral ground glass opacity with reticulation

**Diagnosis: mixed connective tissue disease-associated ILD<sup>1</sup>**

## MONITORING:

- Lung function declined over 6 months<sup>3</sup>
- Respiratory symptoms worsening<sup>3</sup>

**8% decrease in FVC % predicted<sup>3</sup>**

**2% decrease in DL<sub>co</sub> % predicted<sup>3</sup>**

**Declining lung function and worsening symptoms are signs of progressive disease<sup>3</sup>**

DL<sub>co</sub>, diffusing capacity of the lungs for carbon monoxide; FVC, forced vital capacity; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; MCTD, mixed connective tissue disease; NSAID, nonsteroidal anti-inflammatory drug; NSIP, nonspecific interstitial pneumonia; PFT, pulmonary function test.

**Fibrotic ILD is detected and symptoms and lung function are worsening despite immunomodulatory therapy.<sup>5</sup>**

**WHAT IS THE NEXT STEP IN ANN'S DISEASE MANAGEMENT PLAN?**

# ~1 IN 4 PATIENTS WITH ILD MAY DEVELOP A PROGRESSIVE PHENOTYPE<sup>6\*</sup>

## THE INSIDIOUS THREAT OF PULMONARY FIBROSIS CROSSES DIVERSE ILDs<sup>7-9</sup>

- Idiopathic pulmonary fibrosis (IPF)
- Systemic sclerosis-associated ILD
- Rheumatoid arthritis-associated ILD
- Other connective tissue disease-associated ILDs
- Hypersensitivity pneumonitis
- Occupational exposure-related ILDs
- Idiopathic nonspecific interstitial pneumonia
- Unclassifiable ILD
- Sarcoidosis

## SIMILAR TO IPF, SOME ILDs CAN DEVELOP A PROGRESSIVE FIBROSING PHENOTYPE CHARACTERIZED BY<sup>8,9</sup>:



Worsening respiratory symptoms



Accelerated decline in lung function



Worsening quality of life



Early mortality

## EARLY IDENTIFICATION OF ILD IS CRITICAL

Observe for respiratory symptoms<sup>10</sup>:

Listen for<sup>11,12</sup>:

Order baseline PFTs and monitor regularly<sup>10</sup>:

Order HRCT if ILD is suspected<sup>10,13</sup>:



Cough



Dry inspiratory crackles, typically at the lung bases



Restrictive PFT



Presence of fibrotic ILD



Dyspnea



Reduced DL<sub>co</sub>

**EARLY IDENTIFICATION OF PROGRESSIVE PULMONARY FIBROSIS CAN HELP ENSURE PATIENTS RECEIVE APPROPRIATE INTERVENTION<sup>8</sup>**

\*Data from a global, online survey of physicians (N=486).<sup>6</sup>

HRCT, high-resolution computed tomography; IPF, idiopathic pulmonary fibrosis.

**References:** 1. Bodolay E et al. *Rheumatology*. 2005;44(5):656-661. 2. Ungprasert P et al. *Arthritis Care Res*. 2016;68(12):1843-1848. 3. Chan C et al. *BMC Pulm Med*. 2019;19(1):192. 4. NIH.gov. Accessed May 12, 2022. [https://rarediseases.info.nih.gov/diseases/7051/mixed-connective-tissue-disease#ref\\_8047](https://rarediseases.info.nih.gov/diseases/7051/mixed-connective-tissue-disease#ref_8047). Updated January 13, 2016. 5. Kim P, Grossman JM. *Rheum Dis Clin North Am*. 2005;31(3):549-565. 6. Wijsenbeek M et al. *Curr Med Res Opin*. 2019;35(11):2015-2024. 7. Demedts M et al. *Eur Respir J*. 2001;18(suppl 32):2s-16s. 8. Cottin V et al. *Eur Respir Rev*. 2018;27(150). doi:10.1183/16000617.0076-2018 9. Wells AU et al. *Eur Respir J*. 2018;51(5). doi:10.1183/13993003.00692-2018 10. Ryu JH et al. *Mayo Clin Proc*. 2007;82(8):976-986. 11. Silver KC, Silver RM. *Rheum Dis Clin North Am*. 2015;41(3):439-457. 12. Zibrak JD, Price D. *NPJ Prim Care Respir Med*. 2014;24:14054. 13. Walsh SLF et al. *Eur Respir Rev*. 2018;27(150):976-986.